| Title |
NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor
|
|---|---|
| Published in |
Inflammopharmacology, January 2005
|
| DOI | 10.1163/156856005774382661 |
| Pubmed ID | |
| Authors |
James L. Ellis, Michael E. Augustyniak, Edward D. Cochran, Richard A. Earl, David S. Garvey, Laura J. Gordon, David R. Janero, Subhash P. Khanapure, L. Gordon Letts, Terry L. Melim, Madhavi G. Murty, David J. Schwalb, Matthew J. Shumway, William M. Selig, A. Mark Trocha, Delano V. Young, Irina S. Zemtseva |
| Abstract |
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to treat inflammation and to provide pain relief but suffer from a major liability concerning their propensity to cause gastric damage. As nitric oxide (NO) is known to be gastro-protective we have synthesized a NO-donating prodrug of naproxen named NMI-1182. We evaluated two cyclo-oxygenase (COX)-inhibiting nitric oxide donors (CINODs), NMI-1182 and AZD3582, for their ability to be gastro-protective compared to naproxen and for their anti-inflammatory activity. NMI-1182 and AZD3582 were found to produce similar inhibition of COX activity to that produced by naproxen. Both NMI-1182 and AZD3582 produced significantly less gastric lesions after oral administration than naproxen. All three compounds effectively inhibited paw swelling in the rat carrageenan paw edema model. In the carrageenan air pouch model all three compounds significantly reduced PGE2 levels in the pouch exudate but only NMI-1182 and naproxen inhibited leukocyte influx. These data demonstrate that NMI-1182 has comparable anti-inflammatory activity to naproxen but with a much reduced likelihood to cause gastric damage. |
Mendeley readers
The data shown below were compiled from readership statistics for 4 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Uruguay | 1 | 25% |
| China | 1 | 25% |
| Unknown | 2 | 50% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 2 | 50% |
| Professor > Associate Professor | 1 | 25% |
| Unknown | 1 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 1 | 25% |
| Agricultural and Biological Sciences | 1 | 25% |
| Chemistry | 1 | 25% |
| Unknown | 1 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 December 2010.
All research outputs
#7,454,066
of 22,788,370 outputs
Outputs from Inflammopharmacology
#174
of 533 outputs
Outputs of similar age
#36,004
of 139,640 outputs
Outputs of similar age from Inflammopharmacology
#1
of 1 outputs
Altmetric has tracked 22,788,370 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 533 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 139,640 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them